Nasal spray could tame brain inflammation in Alzheimer's – new trial begins
NCT ID NCT06489548
First seen Feb 14, 2026 · Last updated Apr 29, 2026 · Updated 12 times
Summary
This study tests a nasal spray called foralumab in 16 people with early Alzheimer's or mild cognitive impairment. The spray aims to reduce brain inflammation by calming overactive immune cells. Participants will use the spray three times a week for eight weeks and have brain scans, memory tests, and blood draws over six months to check safety and effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Center for Alzheimer Research and Treatment, Brigham and Women's Hospital
RECRUITINGBoston, Massachusetts, 02115, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.